Effect of diclofenac on ocular levels of ciprofloxacin and lomefloxacin in rabbits with endophthalmitis

Drug Development and Industrial Pharmacy

Volumn 40, Issue 11, 2014, Pages 1459-1462

  Krustev, Svetozar Zhelev ^a   Rusenova, Nikolina Velizarova ^a   Haritova, Aneliya Milanova ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

Author keywords

Ciprofloxacin; Endophthalmitis; Lomefloxacin; Rabbit

Indexed keywords

CIPROFLOXACIN; DICLOFENAC; LOMEFLOXACIN; ANTIINFECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; BACTERIAL EYE INFECTION; CONTROLLED STUDY; CORNEA; DRUG EFFECT; DRUG PENETRATION; DRUG POTENTIATION; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EXPERIMENTAL RABBIT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRIS; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; ANIMAL; ANTERIOR EYE SEGMENT; DRUG INTERACTION; METABOLISM; MICROBIAL SENSITIVITY TEST; RABBIT; STAPHYLOCOCCAL INFECTIONS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTERIOR EYE SEGMENT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CIPROFLOXACIN; DICLOFENAC; DRUG INTERACTIONS; ENDOPHTHALMITIS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; RABBITS; STAPHYLOCOCCAL INFECTIONS;

EID: 84911462229     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.828225     Document Type: Article

References (22)

1. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17
2. Bronner S, Jehl F, Peter JD, et al. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother 2003;47:1621-9
3. Dajcs JJ, Thibodeaux BA, Marquart ME, et al. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004;48:1948-52
4. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49:79-83
5. Mather R, Stewart JM, Prabriputaloong T, et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 2004;138:554-9
6. Wada T, Kozai S, Tajika T, et al. Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. J Ocul Pharmacol Ther 2008;24:278-89
7. Öztürk F, Kurt E, Inan UU, et al. The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin. Int J Pharm 2000;204:97-100
8. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-33
9. Giuliano EA. Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology. Vet Clin North Am Small Anim Pract 2004;34: 707-23
10. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229-41
11. Quinn PJ, Carter ME, Markey ME. General procedures in microbiology. In: Quinn PJ, ed. Clinical veterinary microbiology. Mosby: Elsevier Limited; 1999:61-6
12. CSLI (Clinical and Laboratory Standards Institute). Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard-Third edition; CLSI document M31-A3.Wayne, Pennsylvania, USA; 2008
13. Garcia MA, Solans C, Aramayona JJ, et al. Development of a method for the determination of danofloxacin in plasma by HPLC with fluorescence detection. Biomed Chromatogr 2000;14:89-92
14. Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug Dev Ind Pharm [Online] 2012;1-19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23153114 [last accessed 9 July 2013].
15. Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm 2010; 36:108-18
16. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45:3544-7
17. Kowalski RP, Dhaliwal DK, Karenchak LM. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-5
18. García-Vázquez E, Mensa J, Sarasa M, et al. Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration. Eur J Clin Microbiol Infect Dis 2007;26: 137-40
19. Robertson SM, Sanders M, Jasheway D, et al. Penetration and distribution of moxifloxacin and ofloxacin into ocular tissues and plasma following topical ocular administration to pigmented rabbits. Invest Ophthalmol Vis Sci 2003;44: E-Abstract 1454
20. Maurice D. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002;47:41-52
21. Owen GR, Brooks AC, James O, Robertson SM. A novel in vivo rabbit model that mimics human Dosing to determine the distribution of antibiotics in ocular tissues. J Ocul Pharmacol Ther 2007;23: 335-42
22. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50:32-45